• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双重蛋白酶抑制剂洛匹那韦/利托那韦(LPV/r)对肺细胞造成遗传毒性应激。

The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells.

机构信息

SAMRC/UP Precision Prevention and Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, Faculty of Health Sciences, University of Pretoria, Hatfield, 0028, South Africa; Department of Internal Medicine, School of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Parktown, 2193, South Africa.

SAMRC/UP Precision Prevention and Novel Drug Targets for HIV-Associated Cancers Extramural Unit, Pan African Cancer Research Institute, Faculty of Health Sciences, University of Pretoria, Hatfield, 0028, South Africa.

出版信息

Biomed Pharmacother. 2020 Dec;132:110829. doi: 10.1016/j.biopha.2020.110829. Epub 2020 Oct 12.

DOI:10.1016/j.biopha.2020.110829
PMID:33059259
Abstract

The Sub-Saharan countries, particularly South Africa has the largest number of people living with HIV, accompanied by the largest antiretroviral treatment (ART) programme in the world. The Highly Active Antiretroviral Treatment (HAART) is the most effective regimen against HIV/AIDS and has improved the lifespan and quality of life of HIV positive patients. HAART has also led to a decrease in the incidence of AIDS defining cancers (ADCs) while there is an increased incidence of the non-AIDS Defining Cancers (NADCs), such as lung cancer in the HAART era. The association between lung tumourigenesis and the use of HAART components such as the dual protease inhibitor (PI) lopinavir/ritonavir (LPV/r) is poorly understood. Using cell and molecular biological approaches, this study aimed at elucidating the effects of LPV/r on the regulation of the cell cycle related genes in normal (MRC-5) and adenocarcinoma (A549) lung cells. Initially, the nuclear integrity of these cells in response to LPV/r was determined using DAPI staining. The effect of LPV/r on cell cycle genes was evaluated through the use of a RT2 PCR gene array of 84 genes related to the cell cycle signaling pathway. The PCR array data was validated by Real-Time Quantification PCR (RT-qPCR). Ingenuity Pathway Analysis (IPA) bio-informatics tool was employed to disclose the molecular mechanism/s observed at cellular and gene expression levels. Loss of nuclear integrity and the upregulation of the p53 DNA damage response (DDR) pathway was revealed by DAPI staining, differential gene expression and IPA core analysis. Furthermore, MAD2L2 and AURKB which also play a role in the DDR pathway were shown to be differentially expressed. The activation of the CASP3 gene in response to LPV/r in A549 cells was also observed. The findings of this study suggest genotoxic properties of LPV/r in healthy normal lung fibroblasts cells and anti-tumour properties in the A549 cells.

摘要

撒哈拉以南非洲国家,特别是南非拥有世界上数量最多的艾滋病毒感染者,同时也拥有世界上最大的抗逆转录病毒治疗(ART)计划。高效抗逆转录病毒治疗(HAART)是对抗艾滋病毒/艾滋病最有效的方案,它提高了艾滋病毒阳性患者的寿命和生活质量。HAART 还降低了艾滋病定义性癌症(ADCs)的发病率,而非艾滋病定义性癌症(NADCs)的发病率则有所增加,例如在 HAART 时代,肺癌的发病率有所增加。HAART 与肿瘤发生和使用 HAART 成分(如双重蛋白酶抑制剂[PI]洛匹那韦/利托那韦[LPV/r])之间的关联尚未得到充分理解。本研究使用细胞和分子生物学方法,旨在阐明 LPV/r 对正常(MRC-5)和肺腺癌(A549)细胞中细胞周期相关基因调控的影响。首先,通过 DAPI 染色确定这些细胞对 LPV/r 的核完整性。通过使用与细胞周期信号通路相关的 84 个基因的 RT2 PCR 基因芯片评估 LPV/r 对细胞周期基因的影响。PCR 芯片数据通过实时定量 PCR(RT-qPCR)进行验证。采用 IPA 生物信息学工具揭示细胞和基因表达水平观察到的分子机制/。DAPI 染色、差异基因表达和 IPA 核心分析显示,核完整性丧失和 p53 DNA 损伤反应(DDR)途径的上调。此外,还显示 MAD2L2 和 AURKB 这两个也在 DDR 途径中起作用的基因表达差异。还观察到 LPV/r 对 A549 细胞中 CASP3 基因的激活。本研究的结果表明 LPV/r 在健康正常肺成纤维细胞中的遗传毒性特性以及在 A549 细胞中的抗肿瘤特性。

相似文献

1
The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells.双重蛋白酶抑制剂洛匹那韦/利托那韦(LPV/r)对肺细胞造成遗传毒性应激。
Biomed Pharmacother. 2020 Dec;132:110829. doi: 10.1016/j.biopha.2020.110829. Epub 2020 Oct 12.
2
Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer.依非韦伦和洛匹那韦/利托那韦改变肺癌中的细胞周期调控。
Front Oncol. 2020 Aug 28;10:1693. doi: 10.3389/fonc.2020.01693. eCollection 2020.
3
[Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].[洛匹那韦/利托那韦在抗逆转录病毒治疗方案中的定位]
Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:31-4. doi: 10.1016/S0213-005X(14)70166-1.
4
Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.在美国接受过抗逆转录病毒治疗的患者中,洛匹那韦/利托那韦与阿扎那韦加利托那韦相比的成本效益。
Clin Drug Investig. 2007;27(7):443-52. doi: 10.2165/00044011-200727070-00001.
5
[Lopinavir/ritonavir in new initial antiretroviral treatment strategies].[洛匹那韦/利托那韦用于新的初始抗逆转录病毒治疗策略]
Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:7-11. doi: 10.1016/S0213-005X(14)70161-2.
6
[Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].[洛匹那韦/利托那韦用于特殊情况下的人类免疫缺陷病毒感染患者]
Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:18-21. doi: 10.1016/S0213-005X(14)70163-6.
7
Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.洛匹那韦/利托那韦:一种用于治疗HIV-1的蛋白酶抑制剂。
Expert Opin Pharmacother. 2008 Sep;9(13):2363-75. doi: 10.1517/14656566.9.13.2363.
8
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.初治的HIV-1感染患者中,每日一次达芦那韦/利托那韦与洛匹那韦/利托那韦的对比:96周分析。
AIDS. 2009 Aug 24;23(13):1679-88. doi: 10.1097/QAD.0b013e32832d7350.
9
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.在初治抗逆转录病毒治疗受试者中比较洛匹那韦/利托那韦与拉替拉韦以及洛匹那韦/利托那韦与替诺福韦/恩曲他滨的非劣效性、安全性和耐受性:进展研究,48周结果
HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255.
10
The profiling, identification, quantification and analysis of differentially expressed genes (DEGs) in response to drug treatment in lung cancer.肺癌中响应药物治疗的差异表达基因(DEGs)的分析、鉴定、定量和剖析。
MethodsX. 2021 May 11;8:101381. doi: 10.1016/j.mex.2021.101381. eCollection 2021.

引用本文的文献

1
AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.AURKB 通过 MAD2L2 来调控 p53 DNA 损伤反应通路从而促进膀胱癌的进展。
J Transl Med. 2024 Mar 21;22(1):295. doi: 10.1186/s12967-024-05099-6.
2
Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models.洛匹那韦/利托那韦靶向细胞色素P450酶在结直肠癌中的治疗潜力:单层细胞、球体及体内模型研究
Cancers (Basel). 2023 Aug 2;15(15):3939. doi: 10.3390/cancers15153939.
3
Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of Tumour Suppressor Activities.
HIV蛋白酶抑制剂抗人乳头瘤病毒相关宫颈癌的分子机制:肿瘤抑制活性的恢复
Front Mol Biosci. 2022 May 10;9:875208. doi: 10.3389/fmolb.2022.875208. eCollection 2022.
4
COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges.新型冠状病毒肺炎感染与肝损伤:临床特征、生物标志物、潜在机制、治疗及管理挑战
World J Clin Cases. 2021 Aug 6;9(22):6178-6200. doi: 10.12998/wjcc.v9.i22.6178.
5
Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients.核苷/核苷酸类似物及抗逆转录病毒药物拉米夫定的潜在新用途:改善癌症和新冠肺炎患者的治疗效果
Front Oncol. 2021 Jul 21;11:664794. doi: 10.3389/fonc.2021.664794. eCollection 2021.